A clever new tuberculosis vaccine has shown promise in trials in mice. If it succeeds, it will be the first new TB vaccine in a century.
With the rise of multidrug resistant tuberculosis, the difficulty of curing the disease, and the large annual death toll, a successful vaccine could be a huge benefit to public health—especially in low- and middle income countries. The research is published January 13th in Applied and Environmental Microbiology, a journal of the American Society for Microbiology.
The vaccine uses “biobeads” as a platform to present the antigens from the tuberculosis bacterium to the immune system. These biobeads are natural polyesters that certain non-tuberculosis bacteria assemble into tiny spheres. Researchers have engineered them to display antigens from tuberculosis bacteria, Mycobacterium tuberculosis or Mycobacterium bovis. (image: mycobacterium tuberculosis Ziehl-Neelsen stain credit: CDC)
In earlier research, these investigators found that mycobacterial antigens displayed on the biobeads could induce cell-mediated immune responses in mice. Those biobeads were assembled by E.coli. “During these experiments the team observed that along with the tuberculosis antigens, E. coli proteins were attached to the surfaces of the crude biobeads,” said principal investigator Axel Heiser, PhD, Senior Scientist, AgResearch Ltd., Palmerston North, New Zealand.
“From these observations, we developed the hypothesis that these proteins could also function as antigens,” said Heiser. “If produced in Mycobacteria instead of E. coli, such biobeads should carry mycobacterial antigens on their surface, including many as yet undiscovered antigens which would have the potential to induce protective immunity.” And that, in addition to antigens from M. tuberculosis and M. bovis that they would deliberately engineer onto the biobeads, would boost immune response to the vaccine, he said.
But unlike E. coli, Mycobacteria lack the enzymes necessary to assemble biobeads, said Heiser. So they developed new cloning strategies that enabled expression of those enzymes in M. smegmatis, a mycobacterium that does not cause tuberculosis. Using M. smegmatis instead of tuberculosis-causing bacteria would avoid the possibility of the vaccine’s causing tuberculosis infection.
Following production of the biobeads, “We killed and broke up the bacteria, and purified the biobeads,” said Heiser. “They are completely natural, and have been shown to be biodegradable.”
“We then used these mycobacterial biobeads to vaccinate mice and tested the mice for immune responses,” said Heiser. “We saw evidence of cell-mediated immunity with the potential to be protective against TB. Future studies will include a vaccination followed by challenge with TB to show protection, and also the development of more efficient production and purification methods for the vaccine.”
Thus, said Heiser, mycobacterial biobeads would provide a new platform for combining a large antigenic repertoire, comparable to that of live vaccines, with high safety through the use of non-infectious material in the vaccine, including absence of any genetic material. Heiser also said that production would be cost-efficient.
In 2015, 10.4 million people contracted tuberculosis, and 1.8 million died, worldwide, according to the World Health Organization. Nearly half a million of the new cases were multidrug-resistant. 95 percent of the deaths occur in middle- and low-income countries. TB is a leading killer of people with HIV. The only existing vaccine was first used in 1921, and has a variety of shortcomings, including that it can cause the disease in immunocompromised people.
Receive an email update when we add a new TUBERCULOSIS article.
The Latest on: Multidrug resistant tuberculosis
via Google News
The Latest on: Multidrug resistant tuberculosis
- NICE Guidelines on Drug-resistant TBon January 19, 2020 at 11:42 pm
[new 2016] 4. If the rapid diagnostic nucleic acid amplification test for the M. tuberculosis complex is negative in a person at high risk of multidrug‑resistant TB: obtain further specimens for ...
- Antibiotic Resistance Growing With No New Drugs on Horizonon January 17, 2020 at 10:54 am
GENEVA - At least 700,000 people die every year due to drug-resistant diseases, including 230,000 from multidrug resistant tuberculosis, according to the World Health Organization. Last year, a U.N.
- A Patient's Guide to Tuberculosison January 11, 2020 at 5:55 pm
Multidrug-resistant TB is a public health crisis ... "A big misconception is that TB is gone," says Dr. Alfred Lardizabal, executive director of the Global Tuberculosis Institute at Rutgers University ...
- Rwandan doctor discovers rare lineage of a TB causing bacteriaon January 11, 2020 at 2:40 pm
the same family of human-adapted pathogen causing the global tuberculosis pandemic. We realised it in December 2017, after DNA sequencing of a sample collected from patients diagnosed with ...
- Rejuvenating the BCG Vaccineon January 10, 2020 at 2:18 am
tuberculosis is in the body but produces no signs of disease) from progressing to an active disease, for at least 3 years from the date of vaccination. Another such group has produced a drug, that was ...
- 19. Pretomanidon January 2, 2020 at 4:00 am
Specifically, it is approved for patients with multidrug-resistant tuberculosis, which is resistant to the two most powerful anti-TB drugs, and extensively drug-resistant tuberculosis, which is ...
- Annals of the American Thoracic Societyon December 31, 2019 at 4:00 pm
The management of multidrug-resistant tuberculosis (MDR TB) is notably complex among patients with human immunodeficiency virus (HIV). TB treatment recommendations typically include very little ...
- Intermittent treatment interruption and its effect on multidrug resistant tuberculosis treatment outcome in Ethiopiaon December 27, 2019 at 4:37 am
Mycobacterium tuberculosis was isolated by inoculating ... Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment ...
- Multidrug-resistant tuberculosis in children and adolescents in the WHO European Region (2019)on November 8, 2019 at 11:42 pm
This publication is only available online. Evidence-based guidance on how to manage children and adolescents infected with or having active multidrug-resistant tuberculosis (MDR-TB) is needed. The aim ...
via Bing News